Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774779 | 0.91 | MAPT (0.45) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 | |
| SCHEMBL1774892 | 0.86 | MAPT (0.64) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 | |
| SCHEMBL1773691 | 0.86 | MAPT (0.44) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 | |
| SCHEMBL27724674 | 0.85 | MAPT (0.43) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 | |
| SCHEMBL27724665 | 0.85 | KDM4E (0.44) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 | |
| SCHEMBL2174057 | 0.84 | MAPT (0.53) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 | |
| SCHEMBL4704347 | 0.83 | ALDH1A1 (0.39) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 | |
| SCHEMBL1773735 | 0.81 | LMNA (0.46) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 | |
| SCHEMBL1775201 | 0.81 | MEN1 (0.42) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 | |
| SCHEMBL1773447 | 0.79 | MEN1 (0.52) | MAPTALDH1A1SMN1; SMN2SYKMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966212-B1 | DIAZEPINONES | MERCK PATENT GMBH (DE) | 2015-05-13 | — | — | EP | disclosed |
| US-7943608-B2 | Diazepinoes | MERCK PATENT GMBH (DE) | 2011-05-17 | — | — | US | disclosed |
| US-20080318934-A1 | Diazepinoes | MERCK PATENT GESELLSCHAFT (DE) | 2008-12-25 | — | — | US | disclosed |
| EP-1966212-A1 | DIAZEPINONES | Merck Patent GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007079826-A1 | DIAZEPINONES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318934-A1 | Diazepinoes | CDK1, MAP3K11, MAP3K1 | MAPT 904/4885ALDH1A1 1652/4885SMN1; SMN2 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.